Regeneron halting higher doses in fasinumab trials

In its 1Q18 earnings, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said an IDMC recommended discontinuing two higher dose regimens of osteoarthritis (OA) and pain candidate fasinumab (REGN475). Regeneron will modify ongoing trials to continue with two lower doses, President and CSO George Yancopoulos said on a conference call Thursday.

Fasinumab, a mAb against nerve growth factor (NGF), is in Phase III testing to treat OA of the knee and hip, including in patients with chronic low back pain. Regeneron expects the first Phase III efficacy data this year, Yancopoulos said...